|
Variables
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
Adverse DOR (n = 38)
|
Non-adverse DOR (n = 74)
|
P value
|
OR (95 % CI)
|
P value
|
|---|
|
Patient characteristics
|
|
Age (years)
|
34.6 ± 5.0 (33.0–36.3)
|
33.0 ± 4.8 (31.8–34.1)
|
0.09
| | |
|
Gravidity
|
0.2 ± 0.6 (0.03–0.5)
|
0.1 ± 0.4 (0.03–0.2)
|
0.30
| | |
|
Parity
|
0.2 ± 0.6 (0.1–0.6)
|
0.1 ± 0.3 (0–0.2)
|
0.15
| | |
|
Body mass index (kg/m2)
|
21.7 ± 4.5 (20.2–23.2)
|
21.3 ± 5.2 (20.1–22.6)
|
0.73
| | |
|
Laterality of cysts
|
|
Unilateral
|
15 (39.5)
|
49 (66.2)
|
0.007
|
3.71 (1.45–9.51)
|
0.006
|
|
Bilateral
|
23 (60.5)
|
25 (33.8)
| | | |
|
Total size of ovarian cyst (mm)
|
75.4 ± 32.9 (64.6–86.2)
|
71.9 ± 24.4 (66.2–77.5)
|
0.52
| | |
|
Pre-surgical serum hormone concentrations
|
|
LH (mIU/mL)
|
4.7 ± 4.0 (3.4–6.0)
|
6.9 ± 10.0 (4.6–9.2)
|
0.18
| | |
|
FSH (mIU/mL)
|
6.7 ± 2.4 (5.9–7.5)
|
6.4 ± 3.9 (5.4–7.3)
|
0.67
| | |
|
Estradiol (pg/mL)
|
74.1 ± 89.3 (44.8–103.4)
|
71.4 ± 86.7 (51.3–91.5)
|
0.88
| | |
|
CA125 (U/mL)
|
71.3 ± 48.5 (55.4–87.3)
|
67.6 ± 55.4 (54.8–80.4)
|
0.72
| | |
|
AMH (ng/mL)
|
2.5 ± 1.2 (2.1–2.9)
|
4.8 ± 3.1 (4.0–5.5)
|
<0.001
|
0.43 (0.27–0.67)
|
<0.001
|
|
Peri-surgical findings
|
|
Re-ASRM score
|
61.8 ± 33.7 (50.8–72.9)
|
48.9 ± 26.3 (42.8–55.0)
|
0.03
|
−
|
−
|
|
Total surgical duration (min)
|
89.8 ± 40.8 (76.4–103.2)
|
82.8 ± 32.3 (75.3–90.2)
|
0.32
| | |
|
Total blood loss (mL)
|
37.4 ± 45.5 (22.5–52.4)
|
25.4 ± 28.0 (18.9–31.8)
|
0.09
| | |
- Abbreviations: AMH anti-Müllerian hormone, CA125 cancer antigen 125, CI confidence interval, DOR diminished ovarian reserve, FSH follicle-stimulating hormone, LH luteinising hormone, OR odds ratio, Re-ASRM revised American Society of Reproductive Medicine
- Data are expressed as mean ± standard deviation (95 % CI) or number (percentage) of patients
